Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00873119 · ClinicalTrials.gov registry record · Phase 2
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
A Phase 2 study, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00873119 is a Phase 2 study that has completed, run by Valerio Therapeutics. The registered enrollment target is 89 participants.
The verdict
NCT00873119, a Phase 2 study, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
Interventions
- DRUG belinostat, carboplatin, paclitaxel
- DRUG carboplatin, paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00873119
The ClinicalTrials.gov registry entry for NCT00873119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which belinostat, carboplatin, paclitaxel is the first listed.
NCT00873119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00873119 about?
NCT00873119 is a clinical study titled "Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary". The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
What is the current status of trial NCT00873119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2009-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00873119?
The interventions under investigation include: belinostat, carboplatin, paclitaxel (DRUG), carboplatin, paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00873119?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.